Rx Cost Containment At CareFirst Driven By Physician Incentives
This article was originally published in The Pink Sheet Daily
Executive Summary
Legal changes that allow more data sharing can encourage value-based contracting, Executive VP-Medical Affairs Blum says
You may also be interested in...
US Retail Drug Spending Growth Slowing With No New Sovaldis In Sight
Rate of growth in prescription drug spending is expected to average 6.7% per year from 2016 through 2025, National Health Expenditures report from CMS projects.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.
Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?
Insurance plans put on notice that CMS is concerned about restrictions on drugs with negotiated prices, but it’s not clear what the agency can or will do about it.